Idasanutlin

1229705-06-9

C31H29Cl2F2N3O4

DMSO : >= 45 mg/mL (73.00 mM)

Apoptosis

Idasanutlin (RG7388) is a potent and selective MDM2 antagonist, inhibiting p53-MDM2 binding, with an IC₅₀ of 6 nM. IC50 & Target: IC50: 6 nM (p53-MDM2)^[1] In Vitro: Idasanutlin (RG7388) inhibits cell proliferation with IC₅₀ of 30 nM, and induces dose-dependent p53 stabilization, cell cycle arrest, as well as cell apoptosis in cancer cells expressing wild-type p53^[1]. Idasanutlin (RG7388) (300 nM or 1.8 uM) induces apoptosis in SJSA osteosarcoma cells^[2]. In Vivo: Idasanutlin (RG7388, 25 mg/kg p.o.) results in tumor growth inhibition and regression, in the mouse SJSA human osteosarcoma xenograft model^[1]. Idasanutlin (RG7388) induces induction of apoptosis and antiproliferation, in the SJSA xenograft model^[2].